The role of protein oxidation in the development of diabetic microvascular complications

ŞİRANLI, GÜLŞAH; Ozcicek, Adalet; Ersoy, Alevtina; ÇOBAN, T. Abdulkadir; karakurt, yucel; Bektaş, Özcan; Mertoglu, Cuma; gök, gamze; ARSLAN, YUSUF KEMAL

doi:10.14744/nci.2021.33341

The role of protein oxidation in the development of diabetic microvascular complications

CUMA MERTOĞLU, (Department of Clinical Biochemistry, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan Türkiye)

Gulsah Siranli, (2Department of Clinical Biochemistry, Inonu University Faculty of Medicine, Malatya Türkye)

Abdulkadir ÇOBAN, (1Department of Clinical Biochemistry, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan Türkiye)

Yücel KARAKURT, (3Department of Ophthalmology, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan Türkiye)

Alevtina ERSOY, (4Department of Neurology, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan)

Adalet Ozcicek, (5Department of Internal Medicine, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan Türkiye)

YUSUF KEMAL ARSLAN, (6Department of Biostatistics, Erzincan Binali Yildirim University Faculty of Medicine, Erzincan)

Gamze GÖK, (Department of Clinical Biochemistry, Yildirim Beyazit University Faculty of Medicine, Ankara Türkiye)

Özcan BEKTAŞ (7Department of Clinical Biochemistry, Yildirim Beyazit University Faculty of Medicine, Ankara, Türkiye)

İstanbul Kuzey Klinikleri

4 1

Yıl: 2021 Cilt: 8 Sayı: 5 Sayfa Aralığı: 500 - 506 Metin Dili: İngilizce DOI: 10.14744/nci.2021.33341 İndeks Tarihi: 24-05-2022

The role of protein oxidation in the development of diabetic microvascular complications

Öz:

OBJECTIVE: The role of protein oxidation in the development of diabetic microvascular complications was investigated. METHODS: In total, 266 participants were split into five groups: Group 1; diabetes mellitus for at least 10 years without any complications, Group 2; diabetic nephropathy, Group 3; diabetic neuropathy, Group 4; diabetic retinopathy, and Group 5; control group. Thiol, disulfide, ferroxidase, and ischemia-modified albumin (IMA) levels were analyzed in the serum. RESULTS: Native thiol, total thiol, and native thiol/total thiol were lower in Group 4 than Groups 1, 3, and 5 (p<0.001). However, disulfide/native thiol and disulfide/total thiol were higher in Group 4 than all other groups (p<0.001). IMA was higher in Groups 3 and 4 than all other groups (p<0.001). Ferroxidase was lower in Groups 3 and 4 than Group 2 (p<0.001). CONCLUSION: Thiol-disulfide homeostasis impairment in favor of disulfide may have a function in the progress of diabetic retinopathy. Furthermore, the disruptions of IMA and ferroxidase levels involve in the development of diabetic retinopathy and neuropathy.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Park S, Kang HJ, Jeon JH, Kim MJ, Lee IK. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res 2019;42:252–62.
2. Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, et al. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab 2017;102:4343–10.
3. Ergin M, Aydin C, Yurt EF, Cakir B, Erel O. The variation of disulfides in the progression of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2020;128:77–81.
4. Gulpamuk B, Tekin K, Sonmez K, Inanc M, Neselioglu S, Erel O, et al. The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus. Scand J Clin Lab Invest 2018;78:136–42.
5. Eren MA, Koyuncu İ, İncebıyık H, Karakaş H, Erel Ö, Sabuncu T. The evaluation of thiol/disulphide homeostasis in diabetic nephropathy. Diabetes Res Clin Pract 2019;148:249–53.
6. Vural G, Bektas H, Gumusyayla S, Deniz O, Alışık M, Erel O. Impaired thiol-disulphide homeostasis in patients with axonal polyneuropathy. Neurol Res 2018;40:166–72
7. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 2013;65:244–53.
8. Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014;47:326–32.
9. Cremers CM, Jakob U. Oxidant sensing by reversible disulfide bond formation. J Biol Chem 2013;288:26489–96.
10. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 201;49:177–84.
11. Ukinc K, Eminagaoglu S, Ersoz HO, Erem C, Karahan C, Hacihasanoglu AB, et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine 2009;36:425–32.
12. Turk A, Nuhoglu I, Mentese A, Karahan SC, Erdol H, Erem C. The relationship between diabetic retinopathy and serum levels of ischemiamodified albumin and malondialdehyde. Retina 2011;31:602–8.
13. Neselioglu S, Ergin M, Erel O. A new kinetic, automated assay to determine the ferroxidase activity of ceruloplasmin. Anal Sci 2017;33:1339– 44.
14. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018;41:S13–27.
15. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al; Renal Pathology Society. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010;21:556–63.
16. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 2011;27:620–8.
17. Klein R, Klein BE, Magli YL, Brothers RJ, Meuer SM, Moss SE, et al. An alternative method of grading diabetic retinopathy. Ophthalmology 1986;93:1183–7.
18. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001;268:42–7.
19. Kitada M, Zhang Z, Mima A, King GL. Molecular mechanisms of diabetic vascular complications. J Diabetes Investig 2010;1:77–89.
20. Jones DP, Liang Y. Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med 2009;47:1329–38.
21. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005;4:5.
22. Kirboga K, Ozec AV, Kosker M, Dursun A, Toker MI, Aydin H, et al. The association between diabetic retinopathy and levels of ischemia- modified albumin, total thiol, total antioxidant capacity, and total oxidative stress in serum and aqueous humor. J Ophthalmol 2014;2014:820853.
23. Reddy VS, Agrawal P, Sethi S, Gupta N, Garg R, Madaan H, et al. Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy. Eye (Lond) 2015;29:1585–93.
24. Guzman DC, Olguín HJ, García EH, Peraza AV, de la Cruz DZ, Soto MP. Mechanisms involved in the development of diabetic retinopathy induced by oxidative stress. Redox Rep 2017;22:10–6.
25. Duby JJ, Campbell RK, Setter SM, White JR, Rasmusen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004;61:160–73; quiz 175–6.
26. Mertoğlu C, Gunay M, Siranli G, Kulhan M, Gok G, Erel Ö. The effect of the 50 g glucose challenge test on the thiol/disulfide homeostasis in pregnancy. Fetal Pediatr Pathol 2018;37:147–56.
27. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 2008;24:311–7.

APA	Mertoglu C, ŞİRANLI G, ÇOBAN T, karakurt y, Ersoy A, Ozcicek A, ARSLAN Y, gök g, Bektaş Ö (2021). The role of protein oxidation in the development of diabetic microvascular complications. , 500 - 506. 10.14744/nci.2021.33341
Chicago	Mertoglu Cuma,ŞİRANLI GÜLŞAH,ÇOBAN T. Abdulkadir,karakurt yucel,Ersoy Alevtina,Ozcicek Adalet,ARSLAN YUSUF KEMAL,gök gamze,Bektaş Özcan The role of protein oxidation in the development of diabetic microvascular complications. (2021): 500 - 506. 10.14744/nci.2021.33341
MLA	Mertoglu Cuma,ŞİRANLI GÜLŞAH,ÇOBAN T. Abdulkadir,karakurt yucel,Ersoy Alevtina,Ozcicek Adalet,ARSLAN YUSUF KEMAL,gök gamze,Bektaş Özcan The role of protein oxidation in the development of diabetic microvascular complications. , 2021, ss.500 - 506. 10.14744/nci.2021.33341
AMA	Mertoglu C,ŞİRANLI G,ÇOBAN T,karakurt y,Ersoy A,Ozcicek A,ARSLAN Y,gök g,Bektaş Ö The role of protein oxidation in the development of diabetic microvascular complications. . 2021; 500 - 506. 10.14744/nci.2021.33341
Vancouver	Mertoglu C,ŞİRANLI G,ÇOBAN T,karakurt y,Ersoy A,Ozcicek A,ARSLAN Y,gök g,Bektaş Ö The role of protein oxidation in the development of diabetic microvascular complications. . 2021; 500 - 506. 10.14744/nci.2021.33341
IEEE	Mertoglu C,ŞİRANLI G,ÇOBAN T,karakurt y,Ersoy A,Ozcicek A,ARSLAN Y,gök g,Bektaş Ö "The role of protein oxidation in the development of diabetic microvascular complications." , ss.500 - 506, 2021. 10.14744/nci.2021.33341
ISNAD	Mertoglu, Cuma vd. "The role of protein oxidation in the development of diabetic microvascular complications". (2021), 500-506. https://doi.org/10.14744/nci.2021.33341

APA	Mertoglu C, ŞİRANLI G, ÇOBAN T, karakurt y, Ersoy A, Ozcicek A, ARSLAN Y, gök g, Bektaş Ö (2021). The role of protein oxidation in the development of diabetic microvascular complications. İstanbul Kuzey Klinikleri, 8(5), 500 - 506. 10.14744/nci.2021.33341
Chicago	Mertoglu Cuma,ŞİRANLI GÜLŞAH,ÇOBAN T. Abdulkadir,karakurt yucel,Ersoy Alevtina,Ozcicek Adalet,ARSLAN YUSUF KEMAL,gök gamze,Bektaş Özcan The role of protein oxidation in the development of diabetic microvascular complications. İstanbul Kuzey Klinikleri 8, no.5 (2021): 500 - 506. 10.14744/nci.2021.33341
MLA	Mertoglu Cuma,ŞİRANLI GÜLŞAH,ÇOBAN T. Abdulkadir,karakurt yucel,Ersoy Alevtina,Ozcicek Adalet,ARSLAN YUSUF KEMAL,gök gamze,Bektaş Özcan The role of protein oxidation in the development of diabetic microvascular complications. İstanbul Kuzey Klinikleri, vol.8, no.5, 2021, ss.500 - 506. 10.14744/nci.2021.33341
AMA	Mertoglu C,ŞİRANLI G,ÇOBAN T,karakurt y,Ersoy A,Ozcicek A,ARSLAN Y,gök g,Bektaş Ö The role of protein oxidation in the development of diabetic microvascular complications. İstanbul Kuzey Klinikleri. 2021; 8(5): 500 - 506. 10.14744/nci.2021.33341
Vancouver	Mertoglu C,ŞİRANLI G,ÇOBAN T,karakurt y,Ersoy A,Ozcicek A,ARSLAN Y,gök g,Bektaş Ö The role of protein oxidation in the development of diabetic microvascular complications. İstanbul Kuzey Klinikleri. 2021; 8(5): 500 - 506. 10.14744/nci.2021.33341
IEEE	Mertoglu C,ŞİRANLI G,ÇOBAN T,karakurt y,Ersoy A,Ozcicek A,ARSLAN Y,gök g,Bektaş Ö "The role of protein oxidation in the development of diabetic microvascular complications." İstanbul Kuzey Klinikleri, 8, ss.500 - 506, 2021. 10.14744/nci.2021.33341
ISNAD	Mertoglu, Cuma vd. "The role of protein oxidation in the development of diabetic microvascular complications". İstanbul Kuzey Klinikleri 8/5 (2021), 500-506. https://doi.org/10.14744/nci.2021.33341